Epidemiological Insights and Duffy Binding Protein Evolution of *Plasmodium*

***vivax* in Duffy-Negative Cameroonians**

Authors: Cheikh Cambel Dieng[1]*, Rene Teh Ning[2], Canelle Kipayko[1], Regan Schroeder[1],

Nontokozo Mdluli-Berndt[1], Bate Ayukenchengamba[2], Zidedine Nematchoua[2], Sona Doris[2],

Ambendekson Elizabeth Reward[2], Irene Sumbele Ngole Ule[2], Helen Kuokuo Kimbi[2,3], Eugenia

Lo[1]*

Affiliations:

[1]Department of Microbiology and Immunology, College of Medicine, Drexel University

Philadelphia, Pennsylvania, USA

[2]Department of Animal Biology and Conservation (ABC), Faculty of Science, University of

Buea, Buea, Cameroon

[3]Department of Biomedical Sciences, University of Bamenda, Bamenda, Bambili, Cameroon

*Address for correspondence: Cheikh Cambel Dieng, Department of Microbiology and

Immunology, College of Medicine, Drexel University, Philadelphia 19129, Pennsylvania, USA;

email: cd3424@drexel.edu; Eugenia Lo, email: el855@drexel.edu

Short running title: *P. vivax* in Duffy negative Cameroonians

Abstract

Malaria remains a major public health concern in sub-Saharan Africa, and *P. vivax* is emerging in regions with predominantly Duffy-negative populations. This study investigated *P. vivax* prevalence and genetic diversity across three ecological zones in Cameroon. *P. vivax* was detected in ~11% of febrile patients and 5.5% of asymptomatic individuals, all are Duffy-negatives. Clinical infections exhibited higher parasitemia than infections detected in the communities. Standard PvLDH-based RDTs produced false-negative results, even at high parasitemia levels, whereas molecular tools like qPCR demonstrated superior sensitivity. Genetic analysis of *PvDBP1* identified two prevalent mutations, I379L (73%) and E225K (61%), among samples, suggesting adaptive evolution. Phylogenetic analysis clustered Cameroonian isolates with those from Botswana but distinct from the Ethiopian and Sudanese isolates, indicating historical migration and local adaptation. The detection of asymptomatic *P. vivax* cases highlights the potential for transmission, reinforcing the need for enhanced surveillance in both community and clinical settings.

Keywords: Malaria; *Plasmodium vivax*; *Plasmodium falciparum,* Duffy binding protein*,* febrile patients, asymptomatic infections*,* Cameroon

Introduction

Malaria remains a significant global health challenge in sub-Saharan Africa. For decades, *Plasmodium vivax* (*Pv*) was thought to be rare in African populations that lack the Duffy blood group antigen expression. However, emerging evidence has identified *Pv* cases in Duffy-negative individuals across Africa, challenging this conventional dogma. The endemic range of *Pv* has extended beyond the Horn of Africa and penetrated Duffy-negative regions (>95%). A point mutation (c.1–67T>C; rs2814778) in the GATA-1 transcription factor binding site of the Duffy antigen/receptor for chemokines (DARC) gene promoter alters erythroid expression, reducing Duffy antigen expression on the surface of the red blood cells (1, 2).

In sub-Saharan Africa, malaria prevalence varies significantly by region and season. For instance, in Cameroon, the highest prevalence occurs in the western and northern regions that are mostly highlands, which could exhibit different malaria transmission dynamics compared to the lowlands in the eastern region (3). Malaria prevalence also varies significantly by season, ranging from 30% in the dry season from November to February to 65% during the rainy season from March to October. The western part of Cameroon experiences heavy seasonal rainfall, which drives malaria transmission. While *P. falciparum* (*Pf*) remains the dominant parasite species, *Pv* cases have been reported among travelers who acquired infections in Cameroon and were diagnosed after returning to their home countries (4, 5). "*Pv*-like" asymptomatic infections have also been detected by microscopy in schoolchildren in the Mount Cameroon area. Two recent studies also reported an infection rate of 5.6% (6) and 35% (7) of *Pv* in febrile Duffy-negative individuals in Dschang, northwestern Cameroon by PCR. However, most of these studies were case reports and did not assess the broader epidemiological or genetic

characteristics of *Pv* in the region. The extent of genetic polymorphisms of the Duffy Binding

Protein (DBP) gene, a key gene that the parasites use to invade human erythrocytes via DARC

(8), is unclear among *Pv* from Duffy-negative populations in Central Africa. Such variations may

influence the adaptability and geographic spread of *Pv* across Africa.

Environmental factors such as temperature, rainfall, and elevation can shape *Pv*

transmission dynamics through their effects on mosquito vectors and parasite development.

Across Cameroon's diverse ecological zones, these conditions may influence regional patterns of

Pv transmission (9). In this study, we assessed *Pv* prevalence among the northwest, southwest,

and eastern regions of Cameroon in both community and hospital settings. We further examined

Pv genetic polymorphisms from these regions and compared them to isolates from East Africa

and beyond, to evaluate genetic diversity and infer evolutionary relationships. Understanding the

epidemiological and genetic features of *Pv*, particularly in Duffy-negative populations, is

essential for informing malaria surveillance and control strategies in Africa.

Methods

Ethical Statement

The study protocol was approved by the Institutional Review Boards of the Universities of Buea

and Bamenda (Ref No. 2024/2110-06/UB/SG/IRB/FHS). Informed consent was obtained from

all participants or their legal guardians. All methods were carried out in accordance with relevant

guidelines and regulations.

Study Sites and Sample Collection

A cross-sectional study was conducted across three study sites in Cameroon including Bamenda, Buea, and Bertoua. Site selection was based on variation in climate and landscape. Bamenda lies in a highland region (1201–1400 m). Buea, at 530 meters elevation, is a multi-ethnic semi-urban area with year-round malaria transmission (10, 11). Bertoua, in the Eastern region, has a wet equatorial climate and is known for timber and mining industries (9). A total of 1,373 samples (408 samples from Buea, 498 from Bamenda, and 467 from Bertoua) were collected between April and August 2023, of which 793 were from febrile patients at health facilities and 580 from community households. Among all samples, 555 were males and 818 were females. For each individual, 30–50 µL of finger-pricked blood was spotted onto Whatman 3MM filter paper, air-dried, and stored until DNA extraction. Thick and thin blood smears were also prepared for microscopic screening of *Plasmodium*.

***Plasmodium* Screening, Duffy Genotyping, and *PvDBP1* Sequencing**

Plasmodium species were initially determined using rapid diagnostic tests (RDTs; Bioline Malaria Ag Pf/Pv manufactured by Abbott Inc) specific to *Pf* (PfHRP2) and *Pv* (PvLDH), as well as microscopy. Molecular assays were conducted for further diagnosis. Parasitic DNA was extracted from dried blood spots using a modified Chelex®-saponin method (12, 13). Quantitative PCR (qPCR) targeting the 18S rRNA gene was used to identify mono-*Pv* and mixed *Pv-Pf* infections (14). Parasitemia was measured via SYBR Green detection method, using *Pv*-specific primers (S1Table) (13). Each run included positive controls from *Pv* Pakchong (MRA-

342G) and Nicaragua (MRA-340G) isolates, along with negative controls. A standard curve was

generated based on a ten-fold serial dilution of a *Pv* control plasmid to assess amplification

efficiency (E). Specificity of the amplification was verified by melting curve analysis. For each

sample, the mean cycle threshold (Ct) value and standard error were calculated from three

independent runs. Parasitemia was determined using the equation: $2^E \times (40 - Ct_{sample})$.

For each sample, *PvDBP1* region II was also amplified using published primers (forward:

5′-GATATTGATCATAAGAAAACGATCTCTAGT-3′; reverse: 5′-

TGTCACAACTTCCTGAGTATTTTTTTTAGCCTC-3′) (15), designed based on the *P. vivax*

reference sequence PVX_110810 from the Sal I strain (NC_009911.1). The amplification was

performed following the published protocol (15). PCR products were purified prior to Sanger

sequencing. For host Duffy genotyping, a TaqMan qPCR assay was used to examine the point

mutation (c.1–67T>C; rs2814778) of the *DARC* gene (16) . A no-template control was used in

each assay. Genotypes were determined by the allelic discrimination plot. In addition, a 1,100-bp

fragment of the *DARC* gene was further amplified for a subset of samples using published

primers for Sanger sequencing to confirm Duffy genotypes (17).

Data analysis

To evaluate factors associated with mono-*Pv* and mixed *Pv-Pf* infections, odds ratios (OR) and

95% confidence intervals (CI) were calculated for various demographic, clinical, and

epidemiological variables. Demographic variables including gender (male vs. female), age (<5

years, 5–15 years, and >15 years), and collection origin (community vs. hospital-based) were

analyzed to examine the potential risk factors for infection. Symptom-based analyses were

conducted to assess differences in clinical presentation across infection types. MedCalc software

was used for all statistical analysis.

PvDBP1 sequences were aligned to the P01 (PlasmoDB-67_PVP01) reference strain

using MUSCLE in Geneious vX.1. Codon mutations in the Cameroonian *Pv* were compared with

isolates from Thailand and China (Asia), Brazil (South America), Sudan and Ethiopia (East

Africa), and Botswana (Southern Africa) that represent geographically and epidemiologically

diverse regions. Phylogenetic trees were constructed using Maximum Likelihood (ML) method

in RAxML. The ML tree was generated with 1,000 bootstrap replicates. The General Time

Reversible (GTR) model with gamma distribution was used to account for rate heterogeneity.

The resulting tree was imported into FigTree v1.4.4 for visualization. Sequences are available

under GenBank submission number 2920113.

Results

Prevalence of *Pv* infections among Duffy-negatives

The prevalence of mono-*Pv* and mixed *Pv-Pf* infections varied significantly across study sites

(Figure 1). Among 793 hospital samples, mono-*Pv* prevalence was 11% (n=86), mono-*Pf* was

24.5% (n=192), and mixed *Pv-Pf* infections were 13.5% (n=106; Figure 2A, Table 1). All *Pv*

infections were Duffy-negative (CC) per TaqMan genotyping. The highest rates of mono-*Pv* and

mixed *Pv-Pf* infections were found in females over 15 years old in Bamenda (6% and 3.8%).

Among 580 community samples, mono-*Pv* prevalence was 5.5% (n=32), mono-*Pf* was 39.5%

(n=229), and mixed *Pv-Pf* infections were 7.2% (n=42). *Pv* infection rates were comparable

between females (8.9%) and males (8.1%, OR=1.11, *p*=0.597). Similarly, mixed infections

occurred in 11.1% of females and 10.3% of males (OR=1.09, *p*=0.617). No significant

differences in parasitemia were observed between mono- and mixed infections, sexes, or age

groups (Figure 2B; S1 Fig.; S2 Fig.).

Of 119 *Pv*-positive samples by 18S-qPCR, 112 (94%) were confirmed by *PvDBP*1-based

PCR. However, all qPCR-positive samples were microscopy-negative, and only 15 (12.6%) were

RDT-positive (Table 2). These 15 RDT-positive samples showed relatively low Ct values (i.e.,

high parasite DNA copies) by qPCR (Table 2). These findings highlighted the limited sensitivity

of conventional diagnostics in detecting *P. vivax* infections, particularly in Duffy-negative

individuals. While clinical samples had significantly higher average parasitemia than community

samples (*p*<0.001; Figure 3), several community-based (asymptomatic at the time of collection)

infections were shown with relatively high parasitemia. Specifically, 13% of community samples

had parasitemia >1,000 parasites/μL, compared to 21% of hospital cases showing such level of

parasitemia.

Association Between Age, Infection Type, and Symptoms

Age-stratified analysis revealed significant trends in malaria prevalence. Individuals aged 5–15

years had a significantly lower risk of *Pv* infection compared to children under 5 years

(OR=0.67, *p*=0.01). It is not surprising that *Pv* was more common in hospital-based participants

(10.8%) than those from the community (5.5%), though this difference was not statistically

significant (OR=1.16, p=0.162). Likewise, mixed infections were also more common in hospital

(13.3%) than community samples (7.2%), with a significant two-fold increased risk (OR=2.04,

p<0.001). Mono-Pv infections were not associated with specific symptoms, while headache was

significantly associated with *Pf* infections (OR=3.33, p=0.004; Table 3).

Genetic polymorphisms of *PvDBP1* and Phylogenic Relatedness

Eight mutations were identified in the *PvDBP1* region II (amino acid 291-460) among 75 *P.*

vivax isolates from Cameroon. Two of the mutations occurred at high frequency in the Duffy-

negative populations, including I379L observed in 74.1% and E225K in 53.7% of the samples

(Figure 4A). Other less frequent mutations included N372K (27.8%), G339D (22.2%), W442C

(11.1%), K234E (47.1%), K326E (7.4%), and G417V (5.6%). Variants K326E, G339D, N372K,

and I379L were shared with the Thai isolates, though I379L (30%) and G339D (19%) were

observed at considerably lower frequencies in Thailand (Figure 4B). Only K326E and N372K

were shared between the Cameroonian and Botswana isolates. The Chinese *Pv* were the most

polymorphic with 13 variants detected in the binding region, four of which (L333F, N375D,

S398T, and T404R) were unique and not observed elsewhere. The remaining nine variants were

overlapped with the Sudanese, Ethiopian, and Brazilian isolates. However, none of these variants

were detected in the Cameroonian or Botswana *Pv*. The Cameroonian *Pv* shared only N417K

with the Brazilian/East African isolates (Figure 4B).

Phylogenetic analysis revealed distinct clustering of *Pv* isolates by geographic region

(Figure 5A), with East African and Asian *Pv* showing high genetic relatedness, and South

American *Pv* forming a separate clade distinct from the other regions. Within Africa (Figure 5B),

most of the isolates from Cameroon (red) form a distinct cluster, sister to those from Botswana

(light blue). Two other main clades were observed—one contained most of the Ethiopian

(purple) and Ugandan (orange) isolates, and another contained the Ethiopian and Sudanese

(green) isolates—indicating the genetic diversity among the African *P. vivax*.

Discussion

Molecular assays targeting 18S rRNA and *PvDBP1* revealed a substantial number of *Pv*

infections across Cameroon. These findings challenge the longstanding dogma that Duffy-

negative individuals are resistant to *Pv*, suggesting instead that the parasite may have well-

adapted and circulating widely in Central Africa (7, 16, 18). Geographic and environmental

factors strongly influence *Pv* transmission dynamics (19). The southwest region of Cameroon,

like Buea at high altitude on Mount Cameroon, provides favorable conditions such as cooler

temperatures for the development of *Pv*. Unlike *Pf*, which requires warmer temperatures (18°C

and above) mosquito-stage development, *Pv* can survive at 16–18°C, enabling it to transmit in

cooler regions (20). High rainfall and flooding in Buea and Bamenda may enhance transmission

compared to Bertoua (21). Recent studies suggest that malaria is expanding its endemic range to

higher altitudes, including regions such as the Ethiopian highlands (18), Kenya (19), and

Colombia (21). In Ethiopia, *P. vivax* has spread into previously malaria-free highland areas with

a mono-*P. vivax* infection rate of ~8%, similar to our findings in this study. It is apparent that

vivax malaria will increasingly burden the densely populated highlands of Africa and South

America. Due to socio-political unrest and large-scale migration in the English-speaking regions

of Cameroon since 2016, *Pv* may have readily spread to different parts of Cameroon or beyond.

The prevalence of *Pv* infection varied notably by age group. Individuals aged 5–15 years had a

significantly lower risk than children under 5 years, suggesting partial immunity or reduced

exposure (22). The potential spread and adaptation of *P. vivax* emphasizes the need to consider

geographical and environmental heterogeneity when developing malaria control and intervention

strategies.

While hospital-based cases had higher parasitemia, some asymptomatic community

infections were also shown with high parasitemia, indicating transmission potential. In Ethiopia,

Pv in Duffy-negative individuals was observed in both febrile patients and asymptomatic carriers

(23, 24), and some of these infections were detected with gametocytes (25). These findings

emphasize the need for comprehensive surveillance and interventions in both hospital and

community settings. The use of microscopy and RDT diagnostics, though convenient, could have

vastly misidentified or missed low-density *P. vivax* infections. In our study, some individuals

classified as microscopy-negative showed moderate to high parasitemia by qPCR, raising

concerns about the diagnostic sensitivity of microscopy and PvLDH-based RDTs, especially in

Duffy-negative individuals. Similar microscopy results have been reported in a study from

Indonesia(26), where microscopy detected only 5 mixed infections of *P. falciparum* and *P. vivax*,

while nested PCR detected 346 cases across various clinical categories, including asymptomatic

individuals and those recently treated with antimalarials. Notably, all microscopy results were

negative in individuals' post-treatment, while PCR still detected ongoing parasitemia in most

cases(26). Additionally, our findings also suggest that PvLDH-based RDTs may contribute to

false-negative results, even in cases of high parasitemia. This could be attributed to defective or

degraded test kits, lot variability, or antigenic variation that affects the detection capability of

PvLDH in majority Duffy-negative Africa. Molecular tools like qPCR offer superior sensitivity

and specificity, particularly in detecting low-density or mixed *P. vivax* infections in Duffy-

negative individuals, ensuring both symptomatic and asymptomatic carriers are identified and

monitored effectively.

The *PvDBP1* gene encodes a critical ligand that facilitates *P. vivax* invasion of

human erythrocytes by binding to the Duffy antigen receptor, making it a key molecular marker

for both species confirmation and evolutionary analysis. While previous studies in Cameroon

have documented the presence of *P. vivax*, this is the first study to utilize *PvDBP1* not only to

validate *P. vivax* infections in Duffy-negative individuals, but also to examine genetic variations

and phylogenetic relationships of the Cameroonian isolates with global *P. vivax* populations**.** In

the Cameroonian isolates, mutations I379L and E225K occurred at notably high frequencies.

These and several other identified mutations, including K326E, G339D, and N372K overlapped

with *P. vivax* populations from Southeast Asia(27). Mutations I379L and G339D occurred at

substantially higher frequencies in our dataset than other geographical isolates, suggesting

regional adaptation or selective pressures in Central African parasite populations. These findings

highlight the need for future functional assays to clarify their potential role in parasite invasion

and virulence.

Previous studies indicated striking similarity of the *Pv* genome between Asian and East

African parasite populations with high identity-by-descent (20). Our prior research showed no

clear genetic distinction between *Pv* in Duffy-negative and Duffy-positive hosts, indicating

shared ancestry and gene flow (16, 28). This study further shows that Cameroonian and

Botswanan *Pv* form a distinct cluster, separate from East African isolates, likely due to

ecological adaptation and vector diversity. For instance, *Pv* parasites show strong compatibility

with local mosquito vectors (29). In Cameroon and Benin, *Anopheles coluzzii* was identified as a

competent vector for *Pv* (30), suggesting its potential significance in sustaining transmission in

West/Central Africa (31). By contrast, in East Africa, *An. arabiensis* and *An. funestus* are

primary vectors for malaria transmission. While *An. arabiensis* is more commonly associated

with *Pf*, there is evidence suggesting its potential role in transmitting *Pv* (32-34). Such vector

differences may drive *Pv* population divergence between regions.

Apart from vector-parasite co-evolution, host genetic factors may also shape parasite

population structure. Evidence of severe population bottlenecks followed by rapid expansion in

human *Pv*, along with gene pseudogenization (e.g., RBP2d, RBP3) supports host-specific

adaptation in *Pv* (35). East Africa, with a larger Duffy-positive population, likely harbors an

older, more diverse *Pv* gene pool; whereas Central/Southern Africa may represent a portion of

Pv parasites recently introduced from East Africa or constrained populations shaped by

bottlenecks and the predominance of Duffy-negative hosts (35, 36). The observed genetic

relatedness between Cameroonian and Botswanan isolates suggests possible recent gene flow.

The Bantu expansion is the most significant and well-studied migration event between Central

and Southern Africa, where Bantu-speaking people migrated from West-Central Africa,

eventually settling in much of the southern half of the continent and interacting with indigenous

groups like the Khoisan, around 3,000 to 5,000 years ago (37, 38). This migration event could

have shaped the parasite population structure.

This study has a few limitations. First, samples and related metadata were collected at a

single timepoint and thus restricts our ability to assess *Pv* transmission over time. Also, the

genetic analysis based on *PvDBP1* alone does not reflect evolutionary changes at the genome

level for *Pv* in Duffy-negative individuals. The geographic representation of African *Pv* isolates,

particularly samples from West Africa, is limited in the phylogenetic analysis. The apparent

genetic distinctiveness of Central African isolates may change with broader sampling across the

continent. Our ongoing investigations use a genome-based approach together with spatial

analyses to determine source-sink dynamics of *Pv* infections, with the goal to unravel the origin

and adaptation of *Pv* in Africa.

To conclude, the detection of several *Pv* cases in asymptomatic individuals underscores

its potential for silent transmission, emphasizing the need for enhanced surveillance in both

community and clinical settings. PvLDH-based RDTs may contribute to false-negative

diagnostic results, even in cases of high parasitemia. Molecular tools like qPCR offer superior

sensitivity and specificity, particularly in detecting low-density or mixed *Pv* in Duffy-negative

individuals. Our present findings call for tailored malaria control strategies that consider both

geographical/environmental heterogeneity and the unique features of *Pv* in Duffy-negative

populations.

Acknowledgments

We thank the dedicated field team in Cameroon for their invaluable efforts in sample collection,

processing, and logistical support; the communities and hospitals for their support and

willingness to participate in this research; and our collaborators and supporting institutions for

their contributions and insights, which have significantly enriched this research.

Funding

This research was supported by NIH/NIAID R21AI190606. The funding body had no role in the

study design, data collection, analysis, manuscript preparation, or decision to publish.

Disclosure of Interest

The authors declare no conflict of interest.

Table 1. Prevalence of Mono-*Plasmodium vivax*, Mono-*Plasmodium falciparum*, and mixed infections across different sex and age groups in Bamenda, Bertoua and Buea. This table summarizes the infection prevalence of Mono-*Plasmodium vivax* (Mono-Pv), Mono-*Plasmodium falciparum* (Mono-Pf), and Mixed Infections across three sites in Cameroon (Bamenda, Bertoua, and Buea). Data are stratified by sex and age groups (>15 years, <5 years, 5-15 years). For each site, the total number of cases and the percentage distribution of infections are provided. Chi-square tests were conducted to assess the association between infection type (Mono-Pv, Mono-Pf, Mixed) and demographic variables (age group, sex). Significant differences were observed in infection prevalence among different age groups, with higher mixed infection rates observed in females, especially children under 5, indicating a greater vulnerability to mixed infections (p-value < 0.05). Specifically, the highest prevalence of mixed infections was observed in Bamenda (36.54%), followed by Bertoua (34.26%) and Buea (29.20%).

Origin	Site	Sex	Age	Mono-*P.v*	Mono-*P.f*	Mixed Infection	*P.v, P.f* negative	Total
Hospital	Bamenda	Female	>15	6.0% (30)	3.2% (16)	3.8% (19)	27.3% (136)	40.4% (201)
			<5	1.4% (7)	4.4% (22)	3.8% (19)	9.8% (49)	19.5% (97)
			5-15	0.4% (2)	1.0% (5)	0	1.0% (5)	2.4% (12)
		Male	>15	1.2% (6)	1.2% (6)	0.6% (3)	8.6% (43)	11.7% (58)
			<5	1.6% (8)	3.4% (17)	2.4% (12)	16.1% (80)	23.5% (117)
			5-15	0.2% (1)	0	0.2% (1)	2.2% (11)	2.6% (13)
	Buea	Female	>15	5.6% (16)	18.2% (52)	6.7% (19)	15.1% (43)	45.6% (130)
			<5	0.7% (2)	5.6% (16)	1.1% (3)	2.8% (8)	6.7% (29)
			5-15	0.4% (1)	2.8% (8)	2.5% (7)	2.8% (8)	8.5% (24)
		Male	>15	2.8% (8)	7.7% (22)	4.2% (12)	4.2% (12)	18.9% (54)
			<5	1.1% (3)	5.6% (16)	1.8% (5)	2.8% (8)	11.2% (32)
			5-15	0.7% (2)	4.2% (12)	2.1% (6)	2.1% (6)	9.1% (26)

	Total (%)			10.9% (86)	24.5% (192)	13.5% (106)	52.2% (409)	100% (793)

Community	Town	Sex	Age					
Commun ity	**Bertoua**	**Female**	**>15**	0.6% (3)	7.5% (35)	1.9% (9)	11.3% (53)	21.4% (100)
			<5	0.2% (1)	5.1% (24)	0.2% (2)	6.4% (30)	12.2% (57)
			5-15	0.9% (4)	11.3% (53)	0.21% (6)	7.9% (37)	21.4% (100)
		Male	**>15**	0.2% (1)	3.4% (16)	0.6% (3)	4.3% (20)	8.6% (40)
			<5	0.4% (2)	7.1% (33)	0.9% (4)	5.1% (24)	13.5% (63)
			5-15	0.21% (6)	9.9% (46)	1.7% (8)	10.1% (47)	22.9% (107)
	Buea	**Female**	**>15**	6.2% (7)	8.8% (10)	6.2% (7)	38.9% (44)	60.2% (68)
			<5	0	0	0	0	0
			5-15	0	0	0	0	0
		Male	**>15**	6.2% (7)	10.6% (12)	2.7% (3)	19.5% (22)	38.9% (44)
			<5	0.9% (1)	0	0	0	0.9% (1)
			5-15	0	0	0	0	0
	Total (%)			5.5% (32)	39.5% (229)	7.2% (42)	47.8% (277)	100% (580)

Table 2. Detection of *Plasmodium vivax* Infections across Hospital- and Community-Based
Samples. This table shows the *P. vivax* detection using 18S-qPCR, *PvDBP1*-targeted PCR
(DBP-PCR), microscopy, and rapid diagnostic tests (RDTs) in hospital-based (N = 793) and
community-based (N = 580) samples. Most infections, particularly those with higher Ct values
(indicative of lower parasite densities), were undetectable by microscopy and RDT. All qPCR-
positive *P. vivax* samples were from Duffy-negative individuals.
351
352

Hospital-based samples (total *N*= 793)

Ct range by qPCR	18S-qPCR	DBP-PCR+	Microscopic+	RDT+
<20	0	0	0	0
20 - <25	5	5	0	5
25 - <30	17	17	0	7
30 - <35	20	18	0	0
>35 - <38	45	43	0	0

Community-based samples (total *N*= 580)

<20	3	3	0	3
20 - <25	3	2	0	0
25 - <30	1	1	0	0
30 - <35	4	4	0	0
>35 - <38	21	19	0	0

Table 3. Demographic, Geographic, and Symptom-Based Risk Factors Associated with *Plasmodium vivax*, *Plasmodium falciparum*, and Mixed Infections. This table presents the distribution of malaria infections across various demographic, geographic, and clinical symptom categories. Significant associations ($p<0.05$) were observed for several risk factors. Individuals aged 5–15 years had a significantly lower risk of *P. vivax* infection, while those older than 15 years had a higher risk of *P. falciparum* infection. Hospital-based samples had a higher prevalence of mixed infections, and a lower prevalence of *P. falciparum* compared to community-based cases. Among clinical symptoms, headache was significantly associated with *P. falciparum* infection, whereas no other symptoms showed strong associations. These findings suggest that age, geographic origin, and specific clinical presentations contribute to malaria transmission dynamics and severity.

Variables	Number of Samples	Total Infections	Odds ratio [95% CI]	*P. vivax*	Odds ratio [95% CI]	*P. falciparum*	Odds ratio [95% CI]	Mixed Infections	Odds ratio [95% CI]
Overall									
	1373	50.0% [687]		8.6% [118]		30.7% [421]		10.8% [148]	
Sex									
Female	59.5% [818]	58.9% [405]	1	8.9% [73]	1	29.5% [241]	1	11.1% [91]	1
Male	40.4% [555]	41.0% [282]	0.95 [0.77 to 1.18] P= 0.636	8.1% [45]	1.11 [0.75 to 1.64] P= 0.597	32.4% [180]	0.87 [0.69 to 1.09] P= 0.242	10.3% [57]	1.09 [0.77 to 1.55] P= 0.617
Age									
<5	28.8% [396]	28.5% [196]	1	5.9% [23]	1	33.2% [128]	1	11.7% [45]	1
5-15	20.5% [282]	24.6% [168]	0.67 [0.49 to 0.91] P= 0.01*	5.7% [16]	1.03 [0.53 to 1.98] P= 0.941	43.9% [124]	0.61 [0.44 to 0.83] P= 0.002**	9.9% [28]	1.16 [0.71 to 1.91] P= 0.553
>15	50.6% [695]	46.9% [322]	1.14 [0.89 to 1.53] P= 0.314	11.2% [78]	0.49 [0.30 to 0.79] P= 0.004**	24.3% [169]	1.49 [1.13 to 1.95] P= 0.004**	10.8% [75]	1.06 [0.72 to 1.57] P= 0.772

Origin									
Community	42.2% [580]	52.2% [303]	1	5.5% [32]	1	39.5% [229]	1	7.2% [42]	1
Hospital	57.7% [793]	48.4% [384]	1.16 [0.94 to 1.44] **P= 0.162**	10.8% [86]	0.48 [0.32 to 0.73] **P= 0.001****	24.2% [192]	2.04 [1.62 to 2.58] **P < 0.0001****	13.3% [106]	0.51 [0.35 to 0.74] **P= 0.0004****
Symptoms									
Fever	0.3% [4]	0.29% [2]	1	25.0% [1]	1	25.0% [1]	1	0	1
Chills	0	0	1.00 [0.01 to 73.27] **P= 1.000**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.11 [0.00 to 14.76] **P = 0.378**
Abdominal Pain	0.4% [5]	0.29% [2]	1.50 [0.11 to 21.31] **P = 0.765**	0	4.71 [0.15 to 151.49] **P= 0.381**	0	4.71 [0.15 to 151.49] **P= 0.381**	40.0% [2]	0.15 [0.01to 4.39] **P= 0.275**
Headache* (data missing)	0.8% [11]	0.73% [5]	1.20 [0.12 to 11.87] **P= 0.876**	9.1% [1]	3.33 [0.16 to 70.91] **P= 0.440**	9.1% [1]	3.33 [0.16 to 70.91] **P= 0.440**	27.3% [3]	0.27 [0.01 to 6.46] **P= 0.419**
Nausea	0.1% [1]	0	3.00 [0.08 to 115.35] **P= 0.555**	0	1.29 [0.03 to 53.52] **P= 0.895**	0	1.29 [0.03 to 53.52] **P= 0.895**	0	0.33 [0.00 to 25.41] **P= 0.619**
Diarrhea	0.2% [2]	0	5.00 [0.15 to 166.59] **P= 0.368**	0	2.14 [0.06 to 77.54] **P= 0.677**	0	2.14 [0.06 to 77.54] **P= 0.677**	0	0.56 [0.01 to 37.56] **P= 0.785**
Difficulty Breathing	0	0	1.00 [0.01 to 73.27] **P= 1.000**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.11 [0.00 to 14.76] **P= 0.378**
Muscle Pain	0.4% [5]	0.44% [3]	0.67 [0.05 to 9.47] **P= 0.765**	0	4.71 [0.15 to 151.49] **P= 0.381**	0.20% [1]	1.33 [0.06 to 31.12] **P= 0.858**	40.0% [2]	0.16 [0.00 to 4.39] **P= 0.275**

| Fatigue | 0.7% [9] | 0.44% [3] | 2.00 [0.18 to 22.05] **P= 0.571** | 22.2% [2] | 0.67 [0.05 to 9.47] **P= 0.765** | 0 | 8.14 [0.26 to 250.74] **P= 0.230** | 11.1% [1] | 0.63 [0.02 to 18.83] **P= 0.789** |

Figure 1. Study sites across Cameroon (Bamenda, Buea, and Bertoua) by hospital and

community-based collection and infection type including mono-*P. vivax*, mono-*P.*

***falciparum*, mixed *P. vivax* and *P. falciparum*, and negative samples.** The prevalence of

mono-*P. vivax* and mixed *P. vivax*-*P. falciparum* infections showed significant variation across

the study sites.

Figure 2. Comparison of *Plasmodium vivax (Pv)* and *Plasmodium falciparum (Pf)* Infections

Across Hospital and Community Settings and Parasitemia Levels in Mono and Mixed

Infections. (**A**) Panel shows the number of cases for *P. vivax* and mixed *P. vivax* and *P.*

falciparum infections across hospital (orange bars) and community (olive green bars) settings.

Among the hospital samples, 10% (86) were positive for *P. vivax* while 52.3% (409) samples

showed mixed infections, with both *P. vivax* and *P. falciparum* present. In community samples,

5.5% (32) were positive for *P. vivax* and 47.8% (277) samples showed mixed infections.

Figure 3. Comparative Analysis of Parasitemia Levels by Sample Origin in *P. vivax*

Infections. Compares parasitemia levels between hospital and community samples, showing

significantly higher parasitemia in hospital samples.

Figure 4. **Distribution of DBP Gene Mutations in *P. vivax* Isolates from Cameroon and**

Global Comparisons: (A) The bar chart illustrates the frequency of *Plasmodium vivax* Duffy

Binding Protein (DBP) gene mutations in isolates from Cameroon. The mutations E225K,

K234E, K326E, G339D, N372K, I379L, G417V, and W442C were observed with varying

prevalence, with I379L showing the highest frequency. Mutations marked with an asterisk (*)—

K326E, G339D, N372K, and I379L—are also observed in Thailand. (**B**) Comparison of *PvDBP1*

Region II mutations observed in *P. vivax* isolates from Cameroon with those reported in

geographically and epidemiologically diverse regions, including Thailand and China (Asia),

Brazil (South America), Sudan and Ethiopia (East Africa), and Botswana (Southern Africa).

Cameroon shared four mutations (K326E, G339D, N372K, and I379L) with Thailand, though the

frequencies of I379L and G339D were lower in Thai isolates. K326E and I379L were also found

in Botswana. Brazilian and Sudanese/Ethiopian isolates exhibited a broader mutation profile,

including several variants not found in Cameroon. Chinese isolates displayed unique mutations

such as L333F, S398T, and T404R.

Figure 5. Global and Regional Phylogenetic Relationships of *Plasmodium vivax* Isolates.

This figure illustrates the phylogenetic relationships of *Plasmodium vivax* isolates from different

geographical regions using whole genome sequence data: (**A**) Displays a circular phylogenetic

tree that segregates *P. vivax* populations into major global regions, including Central-South

Africa, South America, Asia, and East Africa; (**B**) Presents a radial phylogenetic tree, with color-

coded branches corresponding to isolates from Cameroon (red), Botswana (light blue), Uganda

(orange), Ethiopia (purple), Sudan (green), and reference genomes (yellow). Both trees

demonstrate the genetic diversity and evolutionary divergence of *P. vivax* across different

geographical populations, with significant clustering observed among isolates from specific

regions. The phylogenetic structure highlights potential gene flow and regional adaptation

patterns, particularly in East African populations. These insights are crucial for understanding the

evolutionary history and transmission dynamics of *P. vivax* on both global and regional scales.

References

1.   Dieng CC, Gonzalez L, Pestana K, Dhikrullahi SB, Amoah LE, Afrane YA, et al. Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium falciparum in Ghana: Implications on Seasonal Malaria Chemoprevention. Genes (Basel). 2019 Jul 16;10(7).

2.   King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, et al. Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20113-8.

3.   Ngum NH, Fakeh NB, Lem AE, Mahamat O. Prevalence of malaria and associated clinical manifestations and myeloperoxidase amongst populations living in different altitudes of Mezam division, North West Region, Cameroon. Malar J. 2023 Jan 19;22(1):20.

4.   Gautret P, Legros F, Koulmann P, Rodier M, Jacquemin J-L. Imported Plasmodium vivax malaria in France: geographical origin and report of an atypical case acquired in Central or Western Africa. Acta tropica. 2001;78(2):177-81.

5.   Mangoni ED, Severini C, Menegon M, Romi R, Ruggiero G, Majori G. Case report: An unusual late relapse of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene. 2003;68(2):159-60.

6.   Russo G, Faggioni G, Paganotti GM, Djeunang Dongho GB, Pomponi A, De Santis R, et al. Molecular evidence of Plasmodium vivax infection in Duffy negative symptomatic individuals from Dschang, West Cameroon. Malar J. 2017 Feb 14;16(1):74.

7.   Djeunang Dongho GB, Gunalan K, L'Episcopia M, Paganotti GM, Menegon M, Efeutmecheh Sangong R, et al. Plasmodium vivax Infections Detected in a Large Number of Febrile Duffy-Negative Africans in Dschang, Cameroon. Am J Trop Med Hyg. 2021 Jan 12;104(3):987-92.

8.   Ntumngia FB, McHenry AM, Barnwell JW, Cole-Tobian J, King CL, Adams JH. Genetic

variation among Plasmodium vivax isolates adapted to non-human primates and the implication

for vaccine development. Am J Trop Med Hyg. 2009 Feb;80(2):218-27.

9.   Seraphin EH, Lagarde BJ, Richard P, Jules N, Farrick NO. Diversity, structure and health

of a cocoa based agroforest system in the Humid dense forest, East Cameroon. International

Journal of Biodiversity andConservation. 2021:165.

10.   Akenji T, Ntonifor N, Kimbi H, Abongwa E, Ching J, Anong D, et al. The epidemiology

of malaria in Bolifamba, a rural setting of Mount Cameroon: Seasonal variations in

parasitological indices of transmission [MIM-TA-141660]. ACTA TROPICA; 2005:

ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS; 2005. p.

S295-S6.

11.   Fru-Cho J, Bumah VV, Safeukui I, Nkuo-Akenji T, Titanji VP, Haldar K. Molecular

typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of

Cameroon. Malar J. 2014 May 3;13:170.

12.   Miguel RB, Coura JR, Samudio F, Suárez-Mutis MC. Evaluation of three different DNA

extraction methods from blood samples collected in dried filter paper in Plasmodium subpatent

infections from the Amazon region in Brazil. Rev Inst Med Trop Sao Paulo. 2013;55(3).

13.   Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K, et al. Molecular

epidemiology of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive

and Duffy-negative populations in Ethiopia. Malar J. 2015 Feb 19;14:84.

14.   Abagero BR, Rama R, Obeid A, Tolossa T, Legese F, Lo E, et al. Detection of Duffy

Blood Group Genotypes and Submicroscopic Plasmodium Infections Using Molecular

Diagnostic Assays in Febrile Malaria Patients. Res Sq. 2023 Dec 6.

15.   Gunalan K, Lo E, Hostetler JB, Yewhalaw D, Mu J, Neafsey DE, et al. Role of

Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans. Proc Natl Acad

Sci U S A. 2016 May 31;113(22):6271-6.

16.   Lo E, Russo G, Pestana K, Kepple D, Abagero BR, Dongho GBD, et al. Contrasting

epidemiology and genetic variation of Plasmodium vivax infecting Duffy-negative individuals

across Africa. International Journal of Infectious Diseases. 2021;108:63-71.

17.   Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al.

Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5967-71.

18.   Ketema T, Bacha K, Getahun K, Portillo HAD, Bassat Q. Plasmodium vivax

epidemiology in Ethiopia 2000-2020: A systematic review and meta-analysis. PLoS Negl Trop

Dis. 2021 Sep;15(9):e0009781.

19.   Shanks GD, Hay SI, Omumbo JA, Snow RW. Malaria in Kenya's western highlands.

Emerg Infect Dis. 2005 Sep;11(9):1425-32.

20.   Benavente ED, Manko E, Phelan J, Campos M, Nolder D, Fernandez D, et al. Distinctive

genetic structure and selection patterns in Plasmodium vivax from South Asia and East Africa.

Nat Commun. 2021 May 26;12(1):3160.

21.   Siraj AS, Santos-Vega M, Bouma MJ, Yadeta D, Ruiz Carrascal D, Pascual M.

Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science. 2014

Mar 7;343(6175):1154-8.

22.   Wamae K, Wambua J, Nyangweso G, Mwambingu G, Osier F, Ndung'u F, et al.

Transmission and Age Impact the Risk of Developing Febrile Malaria in Children with

Asymptomatic Plasmodium falciparum Parasitemia. J Infect Dis. 2019 Feb 23;219(6):936-44.

23.   Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.

Comparison of Plasmodium Vivax Infections in Duffy Negatives From Community and Health

Center Collections in Ethiopia. Res Sq. 2023 Oct 3.

24.   Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.

Epidemiology of Plasmodium vivax in Duffy negatives and Duffy positives from community and

health centre collections in Ethiopia. Malar J. 2024 Mar 14;23(1):76.

25.   Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine

candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a

Phase I trial. NPJ Vaccines. 2018;3:48.

26.   Deo DA, Herningtyas EH, Intansari US, Perdana TM, Murhandarwati EH, Soesatyo M.

Difference between Microscopic and PCR Examination Result for Malaria Diagnosis and

Treatment Evaluation in Sumba Barat Daya, Indonesia. Trop Med Infect Dis. 2022 Jul 29;7(8).

27.   Tapaopong P, da Silva G, Chainarin S, Suansomjit C, Manopwisedjaroen K, Cui L, et al.

Genetic diversity and molecular evolution of Plasmodium vivax Duffy Binding Protein and

Merozoite Surface Protein-1 in northwestern Thailand. Infect Genet Evol. 2023 Sep;113:105467.

28.   Kepple D, Hubbard A, Ali MM, Abargero BR, Lopez K, Pestana K, et al. Plasmodium

vivax From Duffy-Negative and Duffy-Positive Individuals Share Similar Gene Pools in East

Africa. J Infect Dis. 2021 Oct 28;224(8):1422-31.

29.   Joy DA, Gonzalez-Ceron L, Carlton JM, Gueye A, Fay M, McCutchan TF, et al. Local

adaptation and vector-mediated population structure in Plasmodium vivax malaria. Mol Biol

Evol. 2008 Jun;25(6):1245-52.

30.   Feufack-Donfack LB, Sarah-Matio EM, Abate LM, Bouopda Tuedom AG, Ngano

Bayibéki A, Maffo Ngou C, et al. Epidemiological and entomological studies of malaria

transmission in Tibati, Adamawa region of Cameroon 6 years following the introduction of long-

lasting insecticide nets. Parasit Vectors. 2021 May 8;14(1):247.

31.   Ossè RA, Tokponnon F, Padonou GG, Glitho ME, Sidick A, Fassinou A, et al. Evidence

of Transmission of Plasmodium vivax 210 and Plasmodium vivax 247 by Anopheles gambiae

and An. coluzzii, Major Malaria Vectors in Benin/West Africa. Insects. 2023 Feb 25;14(3).

32.   Massebo F, Balkew M, Gebre-Michael T, Lindtjørn B. Entomologic inoculation rates of

Anopheles arabiensis in southwestern Ethiopia. Am J Trop Med Hyg. 2013 Sep;89(3):466-73.

33.   Eligo N, Wegayehu T, Pareyn M, Tamiru G, Lindtjørn B, Massebo F. Anopheles

arabiensis continues to be the primary vector of Plasmodium falciparum after decades of malaria

control in southwestern Ethiopia. Malar J. 2024 Jan 9;23(1):14.

34.   Ogola EO, Odero JO, Mwangangi JM, Masiga DK, Tchouassi DP. Population genetics of

Anopheles funestus, the African malaria vector, Kenya. Parasit Vectors. 2019 Jan 8;12(1):15.

35.   Loy DE, Plenderleith LJ, Sundararaman SA, Liu W, Gruszczyk J, Chen YJ, et al.

Evolutionary history of human Plasmodium vivax revealed by genome-wide analyses of related

ape parasites. Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8450-e9.

36.   Abebe A, Dieng CC, Dugassa S, Abera D, Shenkutie TT, Assefa A, et al. Genetic

differentiation of Plasmodium vivax duffy binding protein in Ethiopia and comparison with other

geographical isolates. Malar J. 2024 Feb 23;23(1):55.

37.   Campbell MC, Tishkoff SA. The evolution of human genetic and phenotypic variation in

Africa. Curr Biol. 2010 Feb 23;20(4):R166-73.

38.   Campbell MC, Hirbo JB, Townsend JP, Tishkoff SA. The peopling of the African

continent and the diaspora into the new world. Curr Opin Genet Dev. 2014 Dec;29:120-32.

Figure 1.

Figure 2.

Figure 3.

(A)

(B)

Figure 4.

Figure 5.